Precision Neuroscience Acquires Dallas Factory to Accelerate Development of Brain Implant

Precision Neuroscience, a leading neurotech startup, has recently made a significant stride in its mission to develop groundbreaking brain implant technology. The company announced its acquisition of a factory in Dallas, Texas, where it will manufacture the crucial component of its brain implant, the Layer 7 Cortical Interface. This strategic move aims to expedite development and bring Precision Neuroscience closer to obtaining regulatory approval, which it anticipates securing by 2024.

Precision Neuroscience has already commenced human trials of its brain implant, with the ultimate goal of enabling individuals with paralysis to operate digital devices using their brain signals. The company’s electrode array, thinner than a human hair and resembling a piece of Scotch tape, rests on the brain’s surface and provides real-time, high-resolution rendering of neural activity without causing any tissue damage.

By owning and operating its manufacturing facility, Precision Neuroscience gains the ability to iterate quickly, enhance performance, extend longevity, and explore various form factors for its device. Co-founder and CEO Michael Mager emphasized the advantages of direct involvement in production, including the ability to protect trade secrets, ensure safety, and maintain high-quality standards for the arrays that are implanted in human brains.

The acquisition of the Dallas factory, whose cost remains undisclosed, has allowed Precision Neuroscience to retain the expertise of 11 key personnel who were already familiar with the complex technology. This continuity has been instrumental in ramping up production, as the company can now manufacture over 100 arrays in a single week, a significant improvement over the previous facility’s output.

In addition to streamlining production, the new facility will support Precision Neuroscience’s ongoing regulatory testing and upcoming human trials at the University of Pennsylvania and the Mount Sinai Health System in New York City. The company’s commitment to collaboration with regulators has been recognized by the FDA, which recently granted Precision Neuroscience a Breakthrough Device designation. This designation facilitates a more frequent and efficient line of communication between the company and the FDA, expediting the path to commercialization.

Precision Neuroscience’s momentum, fueled by the manufacturing facility, Breakthrough Device designation, and upcoming trials, positions the company at the forefront of the fast-growing brain-computer interface (BCI) industry. As it continues to innovate alongside other notable players like Neuralink, Synchron, Paradromics, and Blackrock Neurotech, Precision Neuroscience remains dedicated to creating transformative solutions for individuals with debilitating conditions.

With its commitment to safety, rigorous testing, and collaboration with regulatory bodies, Precision Neuroscience is poised to revolutionize the field of neurotechnology. The company’s acquisition of the Dallas factory marks a significant milestone in its journey towards commercializing its brain implant technology and bringing hope to those in need.